Rules for identifying potentially reactive or promiscuous compounds

Journal of Medicinal Chemistry

Volumn 55, Issue 22, 2012, Pages 9763-9772

  Bruns, Robert F ^a   Watson, Ian A ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDEHYDE; AMINE; ARTEMISININ; CHLORPROMAZINE; HALOGEN; KETONE; NITROGEN; PHOSPHORUS; VINYL DERIVATIVE;

ARTICLE; DRUG SCREENING; DRUG STRUCTURE; FLUORESCENCE; GENE TARGETING; PHOTOCHEMICAL QUENCHING;

ANIMALS; BIOLOGICAL ASSAY; DRUG DISCOVERY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MOLECULAR STRUCTURE; PHARMACEUTICAL PREPARATIONS; STRUCTURE-ACTIVITY RELATIONSHIP; TOXICITY TESTS;

EID: 84870026354     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301008n     Document Type: Article

References (39)

1. Shoichet, B. K. Screening in a spirit haunted world Drug Discovery Today 2006, 11, 607-615
2. Thorne, N.; Auld, D. S.; Inglese, J. Apparent activity in high-throughput screening: origins of compound-dependent assay interference Curr. Opin. Chem. Biol. 2010, 14, 315-324
3. McGovern, S. L.; Caselli, E.; Grigorieff, N.; Shoichet, B. K. A common mechanism underlying promiscuous inhibitors from virtual and high-throughput screening J. Med. Chem. 2002, 45, 1712-1722
4. Pearce, B. C.; Sofia, M. J.; Good, A. C.; Drexler, D. M.; Stock, D. A. An empirical process for the design of high-throughput screening deck filters J. Chem. Inf. Model. 2006, 46, 1060-1068
5. Baell, J. B.; Holloway, G. A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays J. Med. Chem. 2010, 53, 2719-2740
6. Rishton, G. M. Reactive compounds and in vitro false positives in HTS Drug Discovery Today 1997, 2, 382-384
7. Hann, M.; Hudson, B.; Lewell, X.; Lifely, R.; Miller, L.; Ramsden, N. Strategic pooling of compounds for high-throughput screening J. Chem. Inf. Comput. Sci. 1999, 39, 897-902
8. Walters, W. P.; Namchuk, M. Designing screens: how to make your hits a hit Nat. Rev. Drug Discovery 2003, 2, 259-266
9. Rishton, G. M. Nonleadlikeness and leadlikeness in biochemical screening Drug Discovery Today 2003, 8, 86-96
10. Open Innovation Drug Discovery. Connecting Compounds to Patients. https://openinnovation.lilly.com/dd/.
11. MSI Cerius2. http://www.chem.cmu.edu/courses/09-560/docs/msi/modenv/D- Files.html#948951
12. Garofalo, A. W.; Wone, D. W. G.; Phuc, A.; Audia, J. E.; Bales, C. A.; Dovey, H. F.; Dressen, D. B.; Folmer, B.; Goldbach, E. G.; Guinn, A. C.; Latimer, L. H.; Mabry, T. E.; Nissen, J. S.; Pleiss, M. A.; Sohn, S.; Thorsett, E. D.; Tung, J. S.; Wu, J. A series of C-terminal amino alcohol dipeptide A[beta] inhibitors Bioorg. Med. Chem. Lett. 2002, 12, 3051-3053
13. Lajiness, M. S.; Maggiora, G. M.; Shanmugasundaram, V. Assessment of the consistency of medicinal chemists in reviewing sets of compounds J. Med. Chem. 2004, 47, 4891-4896
14. OIDD Chemoinformatics Structure Evaluation. https://openinnovation.lilly. com/dd/docs/oidd-cheminformatics-structure-evaluation.pdf.
15. Powers, J. C.; Asgian, J. L.; Ekici, Ö. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases Chem. Rev. 2002, 102, 4639-4750
16. Otto, H.-H.; Schirmeister, T. Cysteine proteases and their inhibitors Chem. Rev. 1997, 97, 133-172
17. Doose, C. A.; Ranke, J.; Stock, F.; Bottin-Weber, U.; Jastorff, B. Structure-activity relationships of pyrithiones: IPC-81 toxicity tests with the antifouling biocide zinc pyrithione and structural analogs Green Chem. 2004, 6, 259-266
18. Committee on Amines. Aromatic Amines: An Assessment of the Biological and Environmental Effects; National Academy Press: Washington, DC, 1981.
19. Waring, M. J. Complex formation between ethidium bromide and nucleic acids J. Mol. Biol. 1965, 13, 269-282
20. Bova, M. P.; Mattson, M. N.; Vasile, S.; Tam, D.; Holsinger, L.; Bremer, M.; Hui, T.; McMahon, G.; Rice, A.; Fukuto, J. M. The oxidative mechanism of action of ortho-quinone inhibitors of protein-tyrosine phosphatase α is mediated by hydrogen peroxide Arch. Biochem. Biophys. 2004, 429, 30-41
21. Lovering, F.; Bikker, J.; Humblet, C. Escape from Flatland: increasing saturation as an approach to improving clinical success J. Med. Chem. 2009, 52, 6752-6756
22. Hogben, C. A. M.; Schanker, L. S.; Tocco, D. J.; Brodie, B. B. Absorption of drugs from the stomach. II. The human J. Pharmacol. Exp. Ther. 1957, 120, 540-545
23. Qinghaosu Antimalarial Coordinating Research Group. Antimalaria studies on qinghaosu Chin. Med. J. 1979, 92, 811-816
24. Rishton, G. M. Molecular diversity in the context of leadlikeness: compound properties that enable effective biochemical screening Curr. Opin. Chem. Biol. 2008, 12, 340-351
25. Verheij, H. Leadlikeness and structural diversity of synthetic screening libraries Mol. Diversity 2006, 10, 377-388
26. 2-lactamase J. Med. Chem. 2008, 51, 2502-2511
27. The Research Group of Jon Tryggvi Njardarson at the University of Arizona. http://cbc.arizona.edu/njardarson/group/.
28. Oprea, T. I.; Davis, A. M.; Teague, S. J.; Leeson, P. D. Is there a difference between leads and drugs? A historical perspective J. Chem. Inf. Comput. Sci. 2001, 41, 1308-1315
29. Boloor, A. C., M.; Davis, R.; Harris, P. A.; Hinkle, K.; Mook, R. A., Jr.; Stafford, J. A.; Veal, J. M. Chemical Compounds. US 2007/0015756 A1, 2007.
30. Ali-Vehmas, T.; Louhi, M.; Sandholm, M. Automation of the resazurin reduction test using fluorometry of microtitration trays J. Vet. Med., Ser. B 1991, 38, 358-372
31. Lor, L. A.; Schneck, J.; McNulty, D. E.; Diaz, E.; Brandt, M.; Thrall, S. H.; Schwartz, B. A simple assay for detection of small-molecule redox activity J. Biomol. Screening 2007, 12, 881-890
32. Baell, J. B. Observations on screening-based research and some concerning trends in the literature Future Med. Chem. 2010, 2, 1529-1546
33. Peters, J.-U.; Hert, J.; Bissantz, C.; Hillebrecht, A.; Gerebtzoff, G.; Bendels, S.; Tillier, F.; Migeon, J.; Fischer, H.; Guba, W.; Kansy, M. Can we discover pharmacological promiscuity early in the drug discovery process? Drug Discovery Today 2012, 17, 325-335
34. Omura, S. I., Y.; Hirano, A.; Nakagawa, A.; Awaya, J.; Tsuchiya, H.; Takahashi, Y.; Masuma, R. A new alkaloid AM-2282 of Streptomyces origin: taxonomy, fermentation, isolation and preliminary characterization J. Antibiot. 1977, 30, 275-282
35. McGovern, S. L.; Shoichet, B. K. Kinase inhibitors: not just for kinases anymore J. Med. Chem. 2003, 46, 1478-1483
36. Feng, B. Y.; Shelat, A.; Doman, T. N.; Guy, R. K.; Shoichet, B. K. High-throughput assays for promiscuous inhibitors Nat. Chem. Biol. 2005, 1, 146-148
37. McGovern, S. L.; Helfand, B. T.; Feng, B.; Shoichet, B. K. A specific mechanism of nonspecific inhibition J. Med. Chem. 2003, 46, 4265-4272
38. Giannetti, A. M.; Koch, B. D.; Browner, M. F. Surface plasmon resonance based assay for the detection and characterization of promiscuous inhibitors J. Med. Chem. 2008, 51, 574-580
39. Ryan, A. J.; Gray, N. M.; Lowe, P. N.; Chung, C.-w. Effect of detergent on "promiscuous" inhibitors J. Med. Chem. 2003, 46, 3448-3451